Skip to content

Greif GEF Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$1.1B-0.5%
Gross profit$247.0M-0.6%
Operating income$35.4M-41.7%
Net income$12.6M-68.4%
EPS (diluted)$1.16-24.6%

Balance sheet

See full
Cash & equivalents$286.1M+42.3%
Total debt$1.2B-60.8%
Total equity$2.9B+44.2%
Total assets$5.6B-15.0%

Cash flow

See full
Operating cash flow$116.6M+479%
CapEx$56.8M+59.1%
Free cash flow$59.8M+190%

Valuation

See full
Market cap$3.92B+19.8%
Enterprise value$4.83B-21.7%
P/E13.1×-3.8×
P/S0.9×+0.1×

Profitability

See full
Gross margin22.4%+1.6pp
Operating margin10.5%+3.4pp
Net margin6.5%+2.3pp
FCF margin5.8%

Returns & leverage

See full
Return on equity12%+2.4pp
Debt / equity0.4×-1.1×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Greif in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: Greif’s 10-K, filed December 23, 2024, on SEC EDGAR. View the filing →

Ask your AI about Greif's capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Greif's capital investments accrued but not yet paid?
Greif (GEF) reported capital investments accrued but not yet paid of $4.18M in Q3 2025.
How has Greif's capital investments accrued but not yet paid changed year-over-year?
Greif's capital investments accrued but not yet paid decreased by 42.6% year-over-year, from $7.28M to $4.18M.
What is the long-term trend for Greif's capital investments accrued but not yet paid?
Over 4 years (2021 to 2025), Greif's capital investments accrued but not yet paid has grown at a -0.7% compound annual growth rate (CAGR), from $17.2M to $16.7M.